See What HealthDay Can Do For You
Contact Us

Experimental Drug Cuts Hepatitis C Viral Load

Earlier treatment failed in 27 of 34 patients

MONDAY, Oct. 30 (HealthDay News) -- The experimental drug VX-950 can provoke a swift drop in viral RNA in patients with chronic hepatitis C, including many for whom earlier treatment had failed, according to the results of a phase 1b trial reported in the October issue of Gastroenterology.

Hendrik W. Reesink, M.D., of the Academic Medical Center in Amsterdam, the Netherlands, and colleagues randomized 34 patients with genotype 1 chronic hepatitis C to placebo or treatment with VX-950, which is a peptide that inhibits the NS3-4A protease. Patients were treated with 450 or 750 milligrams of VX-950 every eight hours or 1,250 mg every 12 hours for two weeks. Prior treatment had failed in 79 percent of patients.

The researchers found that viral loads fell 2 log10 or more in the 28 patients on VX-950; and 3 log10 or more in 93 percent of patients. Trough plasma drug concentrations were highest in the 750-mg group, which had a median hepatitis C virus RNA drop of 4.4 log10 in two weeks. The strongest effect in patients on 450-mg and 1,250-mg doses occurred from days three to seven.

"VX-950 was well tolerated and demonstrated substantial antiviral activity," the authors write. "Some patients had viral breakthrough during dosing, related to selection of variants with decreased sensitivity to VX-950. The results support further studies of VX-950 in patients with chronic hepatitis C."

The study was supported by Vertex Pharmaceuticals, Inc.

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.